NTDs
Planetary Health
Mental Health
AMR
Caregiver
Pharmacy
COVID-19
Global Health Education
Ebola
Natural Hazards
Conflict
Zika
TB
Cholera
HIV
Polio
Rapid Response
Refugee
Disability
Specific Hazards
Social Ethics
MEDBOX is an innovative online library aimed at improving the quality of healthcare in humanitarian action, worldwide.
MEDBOX is an independent internet platform supported by international agencies and scientific institutions active in humanitarian assistance, development and health work worldwide. MEDBOX collates the increasing number of professional guidelines, textbooks and practical documents on health action available online today and brings these into the hands of humanitarian aid and health workers: when they need it, where they need it.
MEDBOX is still under development! We are keen to receiving more documents, training materials and presentations relevant to improve the quality of health action! Your feedback is valuable to us, so do get in touch if you have something you'd like to share with us to improve on, and maximise, our collaborative space. Do send your comments to: news@medbox.org
MEDBOX. Capacity building and quality assurance through innovation.
For more information please go to our section of annual report here
The MEDBOX Team has started a new feature publishing Issue Briefs with different topics.
FILTER BY LANGUAGE
RESULTS/PAGE
LIST TYPE
Human African trypanosomiasis (HAT), also called sleeping sickness, is a parasitic infection that almost invariably progresses to death, unless treatment is provided. HAT caused devastating epidemics during the 20th century. Thanks to sustained and coordinated efforts during the past 15 years the number of reported cases has fallen to a historic low. Fewer than 3,000 cases were reported in 2015, and the disease is targeted for elimination by the World Health Organization. Despite recent success, HAT still poses a heavy burden on the rural communities where this highly focal disease occurs, most notably in Central Africa. Since patients are also reported from non-endemic countries outside Africa, HAT should be considered in differential diagnosis for all travellers, tourists, migrants and expatriates who have visited or lived in endemic areas. In the absence of a vaccine, disease control relies on case detection and treatment, and vector control. Available drugs are sub-optimal, but ongoing clinical trials give hope for safer and simpler treatments ... more
Human African trypanosomiasis (HAT), or sleeping sickness, is an endemic disease in 36 sub-Saharan African countries, typically occurring in underdeveloped areas, where health systems face significant difficulties of diverse natures ... more
Kinetoplastid parasites have caused human disease for millennia. Significant achievements have been made toward developing new treatments for leishmaniasis (particularly on the Indian subcontinent) and for human African trypanosomiasis (HAT). Moreover, the sustained decrease in the incidence of HAT has made the prospect of elimination a tantalizing reality. Despite the gains, no new chemical or biological entities to treat kinetoplastid diseases have been registered in more than three decades, and more work is needed to discover safe and effective therapies for patients with Chagas disease and leishmaniasis. Advances in tools for drug discovery and novel insights into the biology of the host−parasite interaction may provide opportunities for accelerated progress. Here, we summarize the output from a gathering of scientists and physicians who met to discuss the current status and future directions in drug discovery for kinetoplastid diseases ... more
The previous report of the WHO Expert Committee on this disease followed a meeting in 1995. Intensive, coordinated efforts against HAT during the intervening 18 years have resulted in a decrease in incidence to a point at which elimination is considered feasible. This report provides information about new diagnostic approaches, new therapeutic regimens and better understanding of the distribution of the disease with high-quality mapping. The roles of human and animal reservoirs and the tsetse fly vectors that transmit the parasites are emphasized. The new information has formed the basis for an integrated strategy with which it is hoped that elimination of HAT will be achieved. The report also contains recommendations on the approaches that will lead to elimination of the disease ... more
Background: East African trypanosomiasis is an uncommon, potentially lethal disease if not diagnosed and treated in a timely manner. South Africa, as a centre for emergency medical evacuations from much of sub-Saharan Africa, receives a high proportion of these patients, mostly tourists and expatriate residents. Methods: The cases of East African trypanosomiasis patients evacuated to South Africa, for whom diagnostic and clinical management advice was provided over the years 2004–2018, were reviewed, using the authors’ own records and those of collaborating clinicians. Results: Twenty-one cases were identified. These originated in Zambia, Malawi, Zimbabwe, Tanzania, and Uganda. Nineteen cases (90%) had stage 1 (haemolymphatic) disease; one of these patients had fatal myocarditis. Of the two patients with stage 2 (meningoencephalitic) disease, one died of melarsoprol encephalopathy. Common problems were delayed diagnosis, erroneous assessment of severity, and limited access to treatment. Conclusions: The key to early diagnosis is recognition of the triad of geographic exposure, tsetse fly bites, and trypanosomal chancre, plus good microscopy. Elements for successful management are rapid access to specific drug treatment, skilled intensive care, and good laboratory facilities. Clinical experience and the local stock of antitrypanosomal drugs from the World Health Organization have improved the chance of a successful outcome in the management of East African trypanosomiasis in South Africa; the survival rate over the period was 90.5% ... more
In support of the London Declaration goals, PATH aims to catalyze engagement of the diagnostics industry and product development efforts. As part of this work, PATH conducted a diagnostic landscape analysis to identify gaps and evaluated current and nascent HAT diagnostics that may provide solutions. We conducted literature reviews and interviews with key stakeholders to identify use cases for HAT diagnostics, understand current practices, and analyze progress toward more robust diagnostics across different biomarkers ... more
Full Perscribing information on Fexinidazole Tablet for oral use INDICATIONS AND USAGE Fexinidazole Tablets are indicated for the treatment of both the first-stage (hemolymphatic) and second-stage (meningoencephalitic) human African trypanosomiasis (HAT) due to Trypanosoma brucei gambiense in patients 6 years of age and older and weighing at least 20 kg. Limitations of Use Due to the decreased efficacy observed in patients with severe second stage HAT (cerebrospinal fluid white blood cell count (CSF-WBC) >100 cells/μL) due to T. brucei gambiense disease, Fexinidazole Tablets should only be used in these patients if there are no other available treatment options [see Warnings and Precautions (5.1) ... more
Un comité OMS d’experts sur la trypanosomiase humaine africaine (THA) : lutte et surveillance, s’est réuni à Genève (Suisse), du 22 au 26 avril 2013. Le Dr H. Nakatani, sous-directeur général pour le VIH/SIDA, la tuberculose, le paludisme et les maladies tropicales négligées, a ouvert la réunion au nom du Dr M. Chan, directeur-général de l’OMS. La THA est une maladie qui afflige les populations rurales de l’Afrique, là où prolifère la mouche tsé-tsé (ou glossine), vecteur des trypanosomes qui en sont la cause. On distingue deux formes de THA : la forme à T. b. gambiense ou forme gambienne, endémique en Afrique de l’Ouest et en Afrique centrale et qui représente actuellement 95 % des cas, et la forme à T. b. rhodesiense ou forme rhodésienne, endémique en Afrique de l’Est et en Afrique australe, à laquelle sont dus les 5 % restants ... more
The objectives of the meeting were: 1. To step up the commitment of national authorities and technical and financial partners toWHO’s elimination objective for g-HAT. 2. To share achievements, challenges and views on the elimination goal among countries and implementing partners. 3. To assess the status of critical technical aspects to be solved in research and development of drugs and diagnostic tools, epidemiology, vector control and animal reservoirs. 4. To define the mechanisms for strengthening and organizing collaboration and coordination among stakeholders ... more
The objectives of the meeting were: 1. To update the current status of the disease transmission, country capacities and plans for tackling the disease. 2. To understand the epidemiology including disease distribution and risk, the models for estimating under-detection, the geographical variations of in clinical presentation, the roles of domestic and wild animal reservoirs and the subsequent different transmission patterns and control approaches, including vector control. 3. To update current research and development efforts for improving diagnostic and treatment tools. 4. To define the goals for achieving the control of r-HAT, the need for a multisectoral approach and to discuss the strategy for controlling r-HAT and the coordination mechanisms ... more
40 records
Showing 1 to 10 of 40 results
View PDF
Download
Add to my MEDBOX
